COVID-19, Diabete Mellitus
Conditions
Keywords
Glycemic control, Long term medical effects of COVID-19, Blood glucose control, Insulin sensitivity
Brief summary
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
Detailed description
The purpose of this research study is to understand the long-term effects of COVID-19 infection on individuals without any prior history of diabetes. This study will look at several measures of diabetes, such as glycemic control (blood glucose/sugar levels), function of beta cells (cells that make insulin to control sugar), insulin secretion and insulin sensitivity (fasting insulin levels). The following participants will be enrolled: 1) have had COVID-19 infection and were hospitalized and recovered, or 2) have had mild COVID-19 infection and were seen at outpatient clinics or ER and were not required to be hospitalized, or 3) have not had COVID-19 infection but were seen in outpatient clinics or ER during the same time period. The researchers hope to learn the long-term effects of COVID-19 infection in hospitalized patients. Specifically, they will be focusing on the subsequent development of diabetes and associated metabolic disturbances, such as impaired insulin secretion and insulin resistance. A relationship between COVID-19 and diabetes needs to be investigated.
Interventions
OTHERMeasure of physiologic parameters
Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
The University of Texas Health Science Center at San Antonio
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Inclusion criteria
* Body Mass index (BMI) \< 40 kg/m2
Exclusion criteria
* History of diabetes prior to SARS-CoV-2 infection * Took medications used to treat diabetes prior to SARS-CoV-2 infection * History of myocardial infarction or stroke within 6 months * History of major organ system disease prior to COVID-19 infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure of glycosylated glucose percentage (HbA1c) | Baseline to 24 months | Change in HbA1c, and indication of glucose levels over a 3 month period |
| Measure of free plasma glucose (FPG) | Baseline to 24 months | Change in FPG |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body Weight | Baseline to 24 months | Change in body weight over the study period |
Countries
United States
Outcome results
None listed